Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,163 matching trials from the live ClinicalTrials.gov search.
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
40
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Bakersfield, California + 35 more
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Hypercholesterolemia
Interventions
PF-05335810 Dose A, PF-05335810 Dose B, Placebo, PF-04950615 Dose A, PF-05335810 Dose C, PF-04950615, PF-05335810 Dose D, PF-05335810 Dose E
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
New Haven, Connecticut • Miami, Florida • South Miami, Florida + 4 more
Conditions
Graves' Ophthalmopathy (GO)
Interventions
RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection)
Drug · Other
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more
Conditions
COVID-19
Interventions
Peginterferon Lambda-1a, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Claseprubart, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more
Conditions
Atopic Dermatitis
Interventions
Placebo, AK120
Drug
Lead sponsor
Akesobio Australia Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Canoga Park, California • San Diego, California + 11 more
Conditions
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more
Conditions
Generalized Myasthenia Gravis
Interventions
Telitacicept, Placebo
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 26 more
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
30
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Completed Phase 2Phase 3 Interventional Results available

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

NCT04488419
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, New York
Completed Not applicable Interventional Results available

IGF-1 and Bone Loss in Women With Anorexia Nervosa

NCT01406444
Conditions
Anorexia Nervosa, Osteopenia, Osteoporosis
Interventions
rhIGF-1, Risedronate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Anaheim, California • Mission Viejo, California • Westlake Village, California + 12 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Conditions
Hyperlipidemia
Interventions
Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT03999996
Conditions
Dengue Fever
Interventions
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
13 Years to 63 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
8
States / cities
Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Conditions
Burns, Growth Hormone Treatment
Interventions
Somatropin, 0.09% Saline Solution
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
Interventions
Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
51
States / cities
Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more
Conditions
Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions
LV305, G305, LV305-matching placebo, G305-matching placebo
Biological · Other
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
12 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

NCT03383588
Conditions
Pain, Referred
Interventions
Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
17 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York